We present a cross-sectional comparison of all publicly available data across various dimensions such as baseline characteristics, dose titration, efficacy, and safety
Synergistic tissue repair protocol combining two gold-standard healing peptides
FDAs Declaratory Order : FDAs 12-page order describes the process that FDA undertook to come to this conclusion and explains that FDA obtained information both from the manufacturer (Eli Lilly) as well as relevant information from from patients, health care providers, and others, including compounders, along with data from other sources that we independently identified. FDA acknowledges several times in the order that: [E]ven when a shortage is considered resolved, patients and prescribers may still see intermittent localized supply disruptions as products move through the supply chain from the manufacturer and distributors to local pharmacies
They reassert themselves when the pharmacological suppression is removed
On the critical side: nausea in weeks 14 is the most common reason for early discontinuation, and some patients report that the weight loss plateau arrives around month 45 even on the full dose